Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials

INTRODUCTION: Y-TARE) is considered the treatment of choice. AREAS COVERED: Y-TARE in HCC, the recent progress of immunotherapy in this tumor, and the preclinical rationale of combining VEGF blockade with the other two treatment strategies. EXPERT OPINION: Y-TARE might hence overcome primary resistances observed when each of these treatments is administerd alone.